Phase 2 Lung Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are able to give written consent and agree to follow the study schedule and requirements
• People aged 18 years or older
• People who have been diagnosed with stage I non-small cell lung cancer (confirmed by tissue testing under AJCC 9th edition guidelines), with a tumour measuring between 2cm and 4cm
• People whose post-surgery pathology report shows at least one higher-risk feature, such as cancer spreading into the lining around the lung, into blood or lymph vessels, through airspaces, or showing poorly differentiated or high-grade patterns
• People with a general health and activity level rated as fully active or with minor restrictions (ECOG 0 or 1)
• People whose tumour tests positive for a protein called PD-L1 at 1% or more
• People whose tumour does not carry certain gene changes known as EGFR or ALK sensitive mutations
• People who had a complete surgical removal of the tumour with no cancer left behind (called R0 resection)
• People who are within 8 weeks of surgery and have fully recovered from the operation
• People whose liver, kidneys, blood, and other organs are functioning adequately

Who may not be able to join:

• People who have already received any treatment for their current lung cancer, including radiotherapy, chemotherapy, immunotherapy, targeted therapy, or anti-angiogenesis therapy
• People who have previously had radiotherapy to the chest area, including the lung, oesophagus, middle chest, or breast
• People whose lung cancer is of a specific subtype called large-cell neuroendocrine carcinoma, or a mixed type that includes small-cell components
• People whose tumour carries EGFR or ALK sensitive mutations
• People who had only a smaller-scale lung surgery called a segmentectomy or wedge resection (rather than a larger lobe removal)
• People whose tumour involves the main airway tubes, or who have a collapsed or blocked lung related to the tumour
• People with an active autoimmune disease, or a history of an autoimmune disease that has come back
• People with a history of scarring or inflammation of the lung tissue (interstitial lung disease), including cases caused by drugs or previous radiation that required hormone treatment, or who currently have this condition
• People who have needed corticosteroid medicines above a certain dose (more than 10mg per day of prednisone or equivalent) or other immune-suppressing medicines within 14 days before being assigned to a study group
• People who have used certain immune-modifying medicines (such as interferon or interleukin-2) within 4 weeks before the first study dose
• People who have used herbal medicines intended to control cancer within 14 days before the first study dose
• People who have received a live or weakened vaccine within 4 weeks before joining, or who plan to receive one during the study or within 5 months after the last dose of the study drug
• People with a significant history of serious illness or conditions affecting the function of major organs or body systems, as judged by the study doctor
• People who have had a severe ongoing or active infection requiring systemic antibiotic, antifungal, or antiviral treatment (such as tuberculosis) within 14 days before the first study dose
• People known to have HIV infection
• People who have had an organ or stem cell transplant from another person
• People who have had another active cancer within the 2 years before joining, with some exceptions for certain early-stage or fully treated skin cancers, superficial bladder cancer, or pre-invasive cancers (confirm with trial site)
• People with certain personal circumstances, or alcohol or drug dependence, that may affect how the study drug is given, how results are interpreted, or that may increase health risks
• People who are pregnant or breastfeeding, or men and women who plan to try to conceive during the study
• People currently taking part in another interventional clinical trial (observational studies or follow-up-only study phases may be acceptable — confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.